drugset / Trial / NCT07331389
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated
Timeline
- Start
- 2025-09-24
- Primary completion
- 2026-01-12
- Completion
- 2026-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | — | Oral |
| Subject | HDM1002 | Unknown | — | Oral |
| Subject | Metformin | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Valsartan | Unknown | — | Oral |
| Subject | Warfarin | Small molecule | — | Oral |
Indications
No indication recorded.